Thomas Blevins

Summary

Publications

  1. doi request reprint DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac Expressway, Building 3, Suite 200, Austin, Texas 78731, USA
    J Clin Endocrinol Metab 96:1301-10. 2011
  2. doi request reprint Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac, Austin, TX 78731, USA
    Postgrad Med 122:172-83. 2010
  3. doi request reprint Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 diabetes mellitus
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 125:191-204. 2013
  4. pmc Professional continuous glucose monitoring in clinical practice 2010
    Thomas C Blevins
    Texas Diabetes and Endocrinology, Austin, Texas 78731, USA
    J Diabetes Sci Technol 4:440-56. 2010
  5. doi request reprint Control of postprandial glucose levels with insulin in type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 123:135-47. 2011
  6. doi request reprint Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, P A, Austin, TX, USA
    Postgrad Med 122:118-28. 2010

Collaborators

Detail Information

Publications6

  1. doi request reprint DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac Expressway, Building 3, Suite 200, Austin, Texas 78731, USA
    J Clin Endocrinol Metab 96:1301-10. 2011
    ..We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes...
  2. doi request reprint Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, 6500 North Mopac, Austin, TX 78731, USA
    Postgrad Med 122:172-83. 2010
    ..The DPP-4 inhibitors effectively lower glucose and are weight neutral...
  3. doi request reprint Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 diabetes mellitus
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 125:191-204. 2013
    ..This review outlines the benefits of SMBG in the management of patients with T2DM not treated with insulin, and highlights strategies for improving the effectiveness of SMBG-based treatment interventions in this population...
  4. pmc Professional continuous glucose monitoring in clinical practice 2010
    Thomas C Blevins
    Texas Diabetes and Endocrinology, Austin, Texas 78731, USA
    J Diabetes Sci Technol 4:440-56. 2010
    ..Developing a PCGM program at a medical office involves understanding reimbursement issues and having trained staff and a process in place to initiate the test and download and interpret the data...
  5. doi request reprint Control of postprandial glucose levels with insulin in type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, Austin, TX 78731, USA
    Postgrad Med 123:135-47. 2011
    ..Postprandial glucose is an important glycemic burden in many patients; routine targeting and regular monitoring has potential to ameliorate the cardiovascular complications of T2DM...
  6. doi request reprint Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes
    Thomas Blevins
    Texas Diabetes and Endocrinology, P A, Austin, TX, USA
    Postgrad Med 122:118-28. 2010
    ..The objective was to compare the treatment effects between exenatide and insulin, which are 2 injectable peptide hormone-based therapy options for the treatment of type 2 diabetes mellitus...